Evox Therapeutics Company

Orgenesis is a development stage company with a novel therapeutic approach in the treatment of diabetes by correcting malfunctioning organs with new functional tissues created from the patient’s own existing organs. Orgenesis employs a molecular and cellular approach directed at converting liver cells into functional insulin-producing cells as a treatment for diabetes. This new therapeutic approach is called Autologous Insulin Producing (AIP) cell transplantation.
Technology: Other
Industry: Regenerative medicine
Headquarters: United Kingdom
Founded Date: 2016
Employees Number: 11-50
Funding Status: Early Stage Venture
Investors Number: 9
Total Funding: £47.2M
Estimated Revenue: $10M to $50M
Last Funding Type: Grant

Visit Website
enquiries@evoxtherapeutics.com
@evox_ltd
Register and Claim Ownership